Skip to main content

Advertisement

Table 2 Incidence of transfusions

From: Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

  Baseline Hemoglobin < 10 g/dL Baseline Hemoglobin ≥10 g/dL
  Darbepoetin alfa 500 mcg Q3W
N = 176
Darbepoetin alfa 2.25 mcg/kg QW
N = 175
Difference
(Q3W-QW)
Darbepoetin alfa 500 mcg Q3W
N = 177
Darbepoetin alfa 2.25 mcg/kg QW
N = 177
Difference
(Q3W-QW)
Week 5 to EOTP K-M percent (95% CI) [N] 36 (28 to 43) [164] 41 (33 to 49) [167] -5.1 (-16.1 to 5.9) 14 (7 to 20) [171] 21 (14 to 29) [170] -7.3(-17.3 to 2.8)
Week 1 to EOTP K-M percent (95% CI) 44 (37 to 52) 47 (39 to 54) -2.3 (-13.2 to 8.6) 14 (8 to 21) 26 (18 to 33) -11.3 (-21.4 to -1.2)
  1. Q3W = every three weeks; QW = weekly; EOTP = end of the treatment period (defined as the earlier of day 109 or end of study); K-M = Kaplan-Meier